1. Home
  2. GAME vs SCYX Comparison

GAME vs SCYX Comparison

Compare GAME & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GameSquare Holdings Inc.

GAME

GameSquare Holdings Inc.

HOLD

Current Price

$3.06

Market Cap

43.4M

Sector

N/A

ML Signal

HOLD

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$4.64

Market Cap

44.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GAME
SCYX
Founded
2011
1999
Country
United States
United States
Employees
N/A
29
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
43.4M
44.4M
IPO Year
2024
2014

Fundamental Metrics

Financial Performance
Metric
GAME
SCYX
Price
$3.06
$4.64
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$3.00
AVG Volume (30 Days)
174.3K
68.2K
Earning Date
04-08-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
65.14
61.36
EPS
N/A
N/A
Revenue
$44,999,302.00
$257,000.00
Revenue This Year
$87.12
N/A
Revenue Next Year
$21.14
$608.78
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.24
$0.57
52 Week High
$3.85
$6.09

Technical Indicators

Market Signals
Indicator
GAME
SCYX
Relative Strength Index (RSI) N/A 54.19
Support Level N/A $4.65
Resistance Level N/A $5.10
Average True Range (ATR) 0.00 0.33
MACD 0.00 -0.02
Stochastic Oscillator 0.00 67.15

Price Performance

Historical Comparison
GAME
SCYX

About GAME GameSquare Holdings Inc.

GameSquare Holdings Inc is a vertically integrated digital media, entertainment, and technology company focused on gaming and youth culture audiences. The company operates through four reportable segments: Owned and Operated IP, Agency, SaaS and managed services, and Yield. It provides services including influencer marketing, esports talent management, creative production, merchandise and consumer products, live streaming analytics, and digital media solutions through its various brands and platforms. It generates the majority of its revenue from the Agency segment.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: